top of page
Pipeline
Growth Roadmap
From the first technology transfer in 2022,
GeNiner advances toward becoming a global biotech
through a four-stage strategy:
technology transfer → clinical trials → commercialization → IPO.
2029
2026
2028
2024
2025
Salmonella vaccine technology transfer
AIV · IBV technology transfer and approval application
Initiation of royalty revenue streams · GMP facility construction
Global partnership expansion
IPO bid · KRW 4 billion in operating profit
All three markets GeNiner is entering are high-growth sectors with compound annual growth rates (CAGR)? exceeding 5%.
Animal
Vaccines
$113B
Global human vaccine market
CAGR 5.1% (as of 2025)
CAGR 7.2% (as of 2025)
Seasonal
Influenza
$60B
Biopharmaceutical Materials
$10B
Market Scale
Growing Global Markets
bottom of page